Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Rendu Biotechnology CoSHSE:688193 +3.76%59 5-Year Yield-on-Cost % is 2.31 as of Aug. 31, 2026, which is 391% above its 10-year median of 0.47. GuruFocus rates SHSE:688193 with a GF Score™ of 59/100 and a GF Value™ of ¥34.41 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 61 Medical Diagnostics & Research companies, Shanghai Rendu Biotechnology Co ranks worse than 54.1% on this metric.
The historical rank and industry rank for Shanghai Rendu Biotechnology Co's 5-Year Yield-on-Cost % or its related term are showing as below:
SHSE:688193'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.25 Med: 0.47 Max: 2.4
Current: 2.31
During the past 8 years, Shanghai Rendu Biotechnology Co's highest Yield on Cost was 2.40. The lowest was 0.25. And the median was 0.47.
SHSE:688193's 5-Year Yield-on-Cost % is ranked worse than 54.1% of 61
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.61
vs SHSE:688193: 2.31
Shanghai Rendu Biotechnology Co (SHSE:688193) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Shanghai Rendu Biotechnology Co 5-Year Yield-on-Cost % Related Terms
SHSE:688193 vs TMO, DHR, NTRA: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Shanghai Rendu Biotechnology Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Rendu Biotechnology Co 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Shanghai Rendu Biotechnology Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Shanghai Rendu Biotechnology Co's 5-Year Yield-on-Cost % falls into.
Shanghai Rendu Biotechnology Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Shanghai Rendu Biotechnology Co (SHSE:688193) has a 5-Year Yield-on-Cost % of 2.31 as of Aug. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Shanghai Rendu Biotechnology Co and its competitors. This is 391% above median its historical median of 0.47. Over the past decade, Shanghai Rendu Biotechnology Co's 5-Year Yield-on-Cost % has ranged from 0.25 to 2.40. According to the industry distribution chart, Shanghai Rendu Biotechnology Co ranks #33 out of 61 companies in the Medical Diagnostics & Research industry, placing it in the top 54.1%.
Is Shanghai Rendu Biotechnology Co's 5-Year Yield-on-Cost % too high?
Shanghai Rendu Biotechnology Co's current 5-Year Yield-on-Cost % of 2.31 is 391% above median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 2.40. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.61. Shanghai Rendu Biotechnology Co's value of 2.31 is 11.5% below this industry median. Based on the distribution chart, Shanghai Rendu Biotechnology Co ranks #33 out of 61 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Shanghai Rendu Biotechnology Co has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Rendu Biotechnology Co's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Shanghai Rendu Biotechnology Co ranks #33 out of 61 companies for 5-Year Yield-on-Cost %. This places Shanghai Rendu Biotechnology Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.61. Shanghai Rendu Biotechnology Co's value of 2.31 is 11.5% below this benchmark. Historically, Shanghai Rendu Biotechnology Co's own 5-Year Yield-on-Cost % has ranged from 0.25 to 2.40 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 2.61, Shanghai Rendu Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.61, based on 61 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Rendu Biotechnology Co's current 5-Year Yield-on-Cost % of 2.31 is 11.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Shanghai Rendu Biotechnology Co and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Rendu Biotechnology Co's current 5-Year Yield-on-Cost % is 2.31, which is 391% above median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Rendu Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Rendu Biotechnology Co (SHSE:688193) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥34.41, compared to a current price of ¥49.71 — trading 44.5% above its estimated fair value. The current 5-Year Yield-on-Cost % is 2.31, which is 391% above median its 10-year median of 0.47 and 11.5% below the Medical Diagnostics & Research industry median of 2.61. Shanghai Rendu Biotechnology Co's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Shanghai Rendu Biotechnology Co (SHSE:688193), the current 5-Year Yield-on-Cost % is 2.31 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Rendu Biotechnology Co (SHSE:688193) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Rendu Biotechnology Co stock appears to be overvalued.
The current stock price of ¥49.71 is trading 44.5% above its estimated GF Value™ of ¥34.41.
GuruFocus considers Shanghai Rendu Biotechnology Co to be Significantly Overvalued.
Key valuation signals for SHSE:688193:
5-Year Yield-on-Cost %: 2.31 (391% above median its 10-year median of 0.47)
GF Value™: ¥34.41 vs. price of ¥49.71 (44.5% above fair value)
Industry Position: 11.5% below the Medical Diagnostics & Research median (#33 of 61)
No single metric tells the full story. See the SHSE:688193 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Rendu Biotechnology Co Ltd provides solutions for accurate diagnosis, effective prevention and control, as well as personalized diagnosis and treatment of pathogens in the areas of reproduction, respiration, digestion, blood, food, and environmental safety.
59GF Score
Get the complete analysis for SHSE:688193
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688193 has been successfully added to your 
